Corrigendum to “Construction of a novel cancer‑associated fibroblast‑related signature to predict clinical outcome and immune response in cervical cancer” [Transl Oncol. 2024;46:102001]

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-08-23 DOI:10.1016/j.tranon.2025.102499

Zhongxuan Gui , Yingquan Ye , Yu Li , Zhengting Ren , Nan Wei , Li Liu , Hua Wang , Mei Zhang

引用次数: 0

查看原文本刊更多论文

“构建一种新的癌症相关成纤维细胞相关特征来预测宫颈癌的临床结果和免疫反应”的勘误表[Transl Oncol. 2024；46:102001]

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

Corrigendum to “Construction of a novel cancer‑associated fibroblast‑related signature to predict clinical outcome and immune response in cervical cancer” [Transl Oncol. 2024;46:102001]

Corrigendum to “Construction of a novel cancer‑associated fibroblast‑related signature to predict clinical outcome and immune response in cervical cancer” [Transl Oncol. 2024;46:102001]